Technology News and Research

RSS

Officials of Kylin Therapeutics receive an issued patent from USPTO

Officials of Kylin Therapeutics Inc., a leading RNAi company, announced this week that they received an issued patent from the U.S. Patent and Trademark Office.

7 Apr 2010

UHC awards dual 3-year agreements to UHS, Crothall Services Group

University HealthSystem Consortium today announced that after a competitive bid process, it has awarded dual 3-year agreements for clinical/diagnostic equipment maintenance services to Universal Hospital Services, Inc. and Crothall Services Group. Contracts were effective January 1, 2010 and February 1, 2010 respectively.

7 Apr 2010

MEDEC adopts revised, restated Code of Conduct on Interactions with Healthcare Professionals

Effective today MEDEC membership has adopted a revised and restated Code of Conduct on Interactions with Healthcare Professionals.

7 Apr 2010

IZI Medical Products introduces Mammography Indicator Markers

IZI Medical Products today announced that the company has developed and begun distributing two new lines of flat mammography markers, which are being manufactured in the United States and sold worldwide under the brand, Mammography Indicator® Markers.

7 Apr 2010

ESC heart failure meeting encourages audience interaction

"Delegates attending the meeting will get real insights into what's new in heart failure," said Professor Stefan Anker, chairman of the Heart Failure Congress Scientific Committee. "In what's the biggest international stand-alone meeting dedicated to heart failure, there'll be lots of hot of the press news. The very fact that 12 late breaking clinical trial updates are being presented at the meeting demonstrates how bright the future is in heart failure."

7 Apr 2010

Jantibody Therapeutics, Pfenex collaborate in production of HSP-avidin fusion proteins

Boston BioCom LLC today announced the successful completion of a collaborative research agreement between its Jantibody Therapeutics LLC subsidiary and Pfenex Inc., resulting in the rapid production of a HSP-avidin fusion protein for the Jantibodies self-assembling vaccines platform.

7 Apr 2010

Crucell, GSK sign agreement to develop 'second generation malaria vaccine'

Crucell, the Dutch biotechnology company, "said on Tuesday it had agreed with Britain's GlaxoSmithKline to jointly develop a malaria vaccine candidate, without disclosing financial details," Reuters reports (Gray-Block, 4/6).

7 Apr 2010

AbleNet adds Madentec's entire line of assistive technology solutions to product portfolio

AbleNet, Inc. announces the agreement with Madentec Limited of Edmonton, Alberta, Canada for the exclusive global rights to manufacture and sell their entire line of assistive technology solutions. This adds a broad portfolio of proven devices to the AbleNet computer access products. Madentec will continue to own the products and provide engineering development support, which has been their core strength.

7 Apr 2010

SRU Biosystems extends product line with the introduction of BIND SCANNER

SRU Biosystems today announced the extension of its product line of label-free instrumentation and biosensors with the introduction of its BIND® SCANNER for primary and stem cell applications. The BIND SCANNER is a first-of-its-kind, plate-based, label-free instrument capable of monitoring cellular responses at an individual cell resolution.

7 Apr 2010

USPTO issues notice of allowance for vRad's patent applications

Virtual Radiologic Corporation, a national radiology practice and a leader in the development of radiologist workflow technology, received notice of allowance of a patent by the United States Patent and Trademark Office for several applications within its technology portfolio.

7 Apr 2010

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.

7 Apr 2010

Reverse Medical signs strategic partnership agreement with Getz Bros.

Reverse Medical Corporation today announced it has entered into a strategic partnership agreement with Getz Bros. & Company, Inc., for distribution of Reverse Medical devices throughout the Pacific Rim. Getz is an international marketing and medical distribution services company with over 50 offices in 24 countries around the world, and has an excellent reputation for global distribution.

7 Apr 2010

Complex organic molecules speed development of new drugs

Professor Varinder Aggarwal is no ordinary builder. He and his team in the School of Chemistry have just discovered a new technique that could hasten the development of new drugs for today’s incurable diseases – by building complex organic molecules.

7 Apr 2010

Ontario invests millions of dollars in universal flu vaccine campaign

The millions of dollars invested by the province of Ontario in its universal flu vaccine campaign saves lives and is a sensible investment, according to an economic analysis by a researcher at the University of Toronto and the University Health Network.

7 Apr 2010

Adventist Medical Center expands emergency department

Adventist Medical Center (AMC), a southeast Portland, Ore., hospital serving the greater Portland and Vancouver, Wash., metropolitan area, has completed its third and final phase of its emergency department expansion. With this expansion, the hospital now has 32 beds in its emergency department, making it one of the largest in Portland. AMC is also one of the busiest emergency departments in the Portland metro area, serving more than 46,000 patients a year.

7 Apr 2010

MicuRx Pharmaceuticals, Cumencor Pharmaceuticals, Pfizer collaborate to develop antibiotics for MDR-TB

MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc. today announced that the companies have entered a collaboration with Pfizer to discover novel therapeutic agents to treat multi-drug resistant tuberculosis.

7 Apr 2010

Lumenis' 2009 revenues down 12% to $226.1M

Lumenis Ltd., a global leader in developing, manufacturing and distributing a broad range of high-end medical lasers and sophisticated energy delivery equipment for surgical, ophthalmic and aesthetic applications, today announced its financial results for the year ended December 31, 2009 and that it has filed its 2009 annual report on Form 20-F with the U.S. Securities and Exchange Commission.

From Lumenis Inc. 7 Apr 2010

IPS examines malnutrition, obesity in Latin America

Inter Press Service examines malnutrition and factors contributing to the rising rates of "obesity and obesity-related illness - such as type II diabetes, high blood pressure, heart disease, some forms of cancer and osteoporosis - in Latin America, and especially among the poorest sectors of the population."

7 Apr 2010

New web-based technology platform for late phase clinical research

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has introduced a new web-based technology platform for late phase clinical research to meet the expanding regulatory and commercialization needs of the biopharmaceutical industry.

6 Apr 2010

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis. Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

6 Apr 2010